Apollomics, Inc. (APLM) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Foster City, CA, 美国. 现任CEO为 Hung-Wen Chen.
APLM 拥有 IPO日期为 2021-11-26, 13 名全职员工, 在 NASDAQ Capital Marke, 市值为 $15.75M.
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
